Axsome Therapeutics Statistics
Share Statistics
Axsome Therapeutics has 49.24M
shares outstanding. The number of shares has increased by 2.67%
in one year.
| Shares Outstanding | 49.24M |
| Shares Change (YoY) | 2.67% |
| Shares Change (QoQ) | 0.63% |
| Owned by Institutions (%) | 77.28% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 8 |
| FTD / Avg. Volume | n/a |
Short Selling Information
The latest short interest is 4.2M, so 8.6% of the outstanding
shares have been sold short.
| Short Interest | 4.2M |
| Short % of Shares Out | 8.6% |
| Short % of Float | 10.29% |
| Short Ratio (days to cover) | 6.92 |
Valuation Ratios
The PE ratio is -14.11 and the forward
PE ratio is 44.33.
Axsome Therapeutics's PEG ratio is
-1.03.
| PE Ratio | -14.11 |
| Forward PE | 44.33 |
| PS Ratio | 10.51 |
| Forward PS | 2 |
| PB Ratio | 71.1 |
| P/FCF Ratio | -31.5 |
| PEG Ratio | -1.03 |
Financial Ratio HistoryEnterprise Valuation
Currently the Enterprise Value (EV) is not available for Axsome Therapeutics.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.11,
with a Debt / Equity ratio of 3.38.
| Current Ratio | 2.11 |
| Quick Ratio | 2.04 |
| Debt / Equity | 3.38 |
| Debt / EBITDA | -0.71 |
| Debt / FCF | -1.5 |
| Interest Coverage | -42.71 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $541,703.65 |
| Profits Per Employee | $-403,393.26 |
| Employee Count | 712 |
| Asset Turnover | 0.68 |
| Inventory Turnover | 2.12 |
Taxes
| Income Tax | 85K |
| Effective Tax Rate | -0.03% |
Stock Price Statistics
The stock price has increased by 48.57% in the
last 52 weeks. The beta is 0.45, so Axsome Therapeutics's
price volatility has been higher than the market average.
| Beta | 0.45 |
| 52-Week Price Change | 48.57% |
| 50-Day Moving Average | 113.54 |
| 200-Day Moving Average | 99.74 |
| Relative Strength Index (RSI) | 46.37 |
| Average Volume (20 Days) | 865,468 |
Income Statement
In the last 12 months, Axsome Therapeutics had revenue of 385.69M
and earned -287.22M
in profits. Earnings per share was -5.99.
| Revenue | 385.69M |
| Gross Profit | 352.39M |
| Operating Income | -280.56M |
| Net Income | -287.22M |
| EBITDA | -272.6M |
| EBIT | -280.56M |
| Earnings Per Share (EPS) | -5.99 |
Full Income StatementBalance Sheet
The company has 315.35M in cash and 192.96M in
debt, giving a net cash position of 122.4M.
| Cash & Cash Equivalents | 315.35M |
| Total Debt | 192.96M |
| Net Cash | 122.4M |
| Retained Earnings | -1.12B |
| Total Assets | 596.67M |
| Working Capital | 250.72M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -128.41M
and capital expenditures -270K, giving a free cash flow of -128.68M.
| Operating Cash Flow | -128.41M |
| Capital Expenditures | -270K |
| Free Cash Flow | -128.68M |
| FCF Per Share | -2.69 |
Full Cash Flow StatementMargins
Gross margin is 91.37%, with operating and profit margins of -72.74% and -74.47%.
| Gross Margin | 91.37% |
| Operating Margin | -72.74% |
| Pretax Margin | -74.45% |
| Profit Margin | -74.47% |
| EBITDA Margin | -70.68% |
| EBIT Margin | -72.74% |
| FCF Margin | -33.36% |
